A promising treatment for dementia

Credit: Pixabay / CC0 Domain Public

A study led by Monash University has found an exciting new treatment for patients with post-traumatic stress disorder, the second most common type of dementia in the under-60s — who results in an imbalance of what constitutes behavioral issues, as well as mental retardation. reduction due to disease. It is the second clinical trial to show that the drug, sodium selenate, may delay cognitive decline and neurodegenerative damage which is a symptom of many diseases including Alzheimer’s disease.

Gabatotemporal variability rabies (bvFTD) is a highly contagious disease and can occur in people over the age of 35. It is characterized by behavioral disorders and behavior changes and can be very stressful and stressful for both patients and their families. There is currently no cure or cure for bvFTD and daily life is 5-7 years from diagnosis.

A Phase 1 trial conducted with Royal Melbourne Hospital, Australia’s only non-genetic bvFTD target, and one of the largest in the world, showed that the drug, sodium selenate is safe and stable in patients with bvFTD within 12 months. Importantly, the majority of patients receiving sodium selenate showed no change in their perception or behavior, and reduced brain atrophy during testing. Test results by Dr. Led by Lucy Vivash, from the Department of Neuroscience of Monash University, it is published in the journal. Alzheimer’s and Dementia: A Translation and Clinical Study.

In about half of cases with bvFTD, damage to neurons in the brain results in the development of a protein called tau. This protein is the main target of research for the prevention and treatment of Alzheimer’s disease and other mental illnesses, as a way to expose the neurodegeneration caused by this disorder.

According to Dr. Vivash, sodium selenate regulates an enzyme in the brain that breaks down protein effectively. “We have shown previously, in Phase 2 experiments, that sodium selenate given to patients with mild to moderate Alzheimer’s disease caused lower neurodegeneration than those who did not,” she said. Significantly those patients in the experiment with higher selenium levels, a sodium selenate breakdown product, in their blood showed a slight decrease. cognitive decline.

The research team is currently conducting a large-scale study in several hospitals across Australia and New Zealand to further test whether this treatment is beneficial for patients with bvFTD.

Early alcohol consumption may be a sign of illness, researchers have found

Learn more:
Lucy E Vivash et al. Alzheimer’s & Dementia (2021). DOI: 10.1002 / alz.050979

hintSodium selenate: An interesting treatment for dementia (2022, May 5) Retrieved 5 May 2022 from

This document is copyrighted. Apart from any genuine transaction for the purpose of personal analysis or investigation, no part may be reproduced without our written permission. Content is provided for informational purposes only.

A promising treatment for dementia Source link A promising treatment for dementia

Related Articles

Back to top button